Format

Send to

Choose Destination
Rheumatol Int. 2011 Jan;31(1):89-91. doi: 10.1007/s00296-009-1146-6. Epub 2009 Sep 30.

Churg-Strauss syndrome successfully treated with rituximab.

Author information

1
Division of Internal Medicine, Department of Rehabilitation, Stavanger University Hospital, Stavanger, Norway.

Abstract

Churg-Strauss syndrome (CSS) is characterized by small-vessel vasculitis, extravascular granulomatous inflammation, and massive eosinophilia in tissues and blood, and is often accompanied by a history of preclinical asthma and/or allergic rhinitis lasting several years before the syndrome develops its full clinical picture. Corticosteroids, often in combination with cytotoxic agents, comprise standard therapy; however, a number of patients appear to be resistant to treatment and there is a need for more effective regimens. B cell depletion may be an effective treatment option for CSS. Here, we describe two patients resistant to conventional therapy who were treated with rituximab and experienced a rapid and substantial decrease in disease activity and asthmatic symptoms and an increase in physical capacity.

PMID:
19789874
DOI:
10.1007/s00296-009-1146-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center